<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513669</url>
  </required_header>
  <id_info>
    <org_study_id>PMAL03</org_study_id>
    <nct_id>NCT00513669</nct_id>
  </id_info>
  <brief_title>Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania</brief_title>
  <acronym>PMAL03</acronym>
  <official_title>A Phase Ib Double-blind Randomized Placebo Controlled Age-deescalating Trial of Two Virosome Formulated Anti-malaria Vaccine Components (PEV 301 and PEV 302) Administered in Combination to Healthy Semi-immune Tanzanian Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mymetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pevion Biotech Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Tropical &amp; Public Health Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ib double-blind randomized placebo controlled age-deescalating trial to&#xD;
      assess sagety and immunogenicity of two virosome formulated anti-malaria vaccine components&#xD;
      (PEV 301 and PEV 302) administered in combination to healthy semi-immune Tanzanian adult and&#xD;
      children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volunteers will be screened, enrolled, injected with the vaccine or comparator and followed&#xD;
      by the clinicians at the Bagamoyo Research and Training Unit of the the Ifakara Health&#xD;
      Research and Development Center (BRTU-IHRDC).&#xD;
&#xD;
      First, 10 adult males will be enrolled and randomized in 2 groups: Group AV (n=8) will be&#xD;
      injected with the vaccine combination and group AP (n=2) will be vaccinated with the&#xD;
      placebo=comparator (Inflexal V). 5 weeks later, 8 children will be enrolled first and&#xD;
      randomized in 2 groups: Group CV (n=6) will be injected with the vaccine combination and&#xD;
      group CP (n=2) will be vaccinated with comparator. 1 week later, the rest of the cohort&#xD;
      (n=32) will be enrolled and randomized in 2 groups: Group CV (n=26) will be injected with the&#xD;
      vaccine combination and group CP (n=6) will be vaccinated with comparator.&#xD;
&#xD;
      Immunogenicity assessments for humoral immune response will be made at baseline (days -10 to&#xD;
      -2), day 30 (+4), day 90 (+4) (day of 2nd vaccination), 120 (+4), 180 (+7), and 365 (+14).&#xD;
&#xD;
      Cellular immune responses will be assessed before 1st vaccination (day 0), two weeks after&#xD;
      2nd vaccination (day 104 ±2), and one year after the 1st vaccination (day 365) Safety&#xD;
      assessments will be made by the investigator at baseline (days -10 to -2, before the 1st&#xD;
      immunization) and at day 1, 2, 3, 7, 14, 30 after each vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (incidence of local and systemic adverse events) Humoral immunity</measure>
    <time_frame>30 days post-injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated immunity</measure>
    <time_frame>14 days post-injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>1 PEV301&amp;302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The vaccine includes two antigens (CSP and AMA1- derived)in combination and formulated with virosomes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inflexal V is the comparator that includes 3 antigens from flu formulated in virosomes</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEV 301&amp; 302 in virosomes</intervention_name>
    <description>PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90</description>
    <arm_group_label>1 PEV301&amp;302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inflexal V (active comparator)</intervention_name>
    <description>Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90</description>
    <arm_group_label>2 Influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male volunteers aged between 18 and 45 years for the adult group, and children of both&#xD;
             sexes aged 5-9 years for schoolchildren group&#xD;
&#xD;
          2. Written informed consent obtained from the volunteer (adult) or guardian/ legal&#xD;
             representative (children). In case patient is illiterate, an impartial witness should&#xD;
             be present during the entire consent procedure&#xD;
&#xD;
          3. Free of obvious health problems as established by medical history and clinical&#xD;
             examination before entering the study&#xD;
&#xD;
          4. Body Mass Index between 18 and 30 for adults; MUAC less than 12 for children&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any investigational or non-registered drug or vaccine within 30 days preceding&#xD;
             the first dose of study vaccine, or planned use during the study period and safety&#xD;
             follow-up&#xD;
&#xD;
          2. Chronic administration (defined as more than 14 days) of immunosuppressants or other&#xD;
             immune-modifying drugs within six months prior to the first vaccine dose&#xD;
&#xD;
          3. Any chronic drug therapy to be continued during the study period&#xD;
&#xD;
          4. Any confirmed or suspected acquired immunosuppressive or immunodeficient condition,&#xD;
             including human immunodeficiency virus (HIV) infection, or history of congenital or&#xD;
             hereditary immunodeficiency&#xD;
&#xD;
          5. History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine&#xD;
&#xD;
          6. Acute disease at the time of enrollment. Acute disease is defined as the presence of a&#xD;
             moderate or severe illness with or without fever (defined as temperature more than&#xD;
             37.5°C)&#xD;
&#xD;
          7. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal&#xD;
             functional abnormality, as determined by physical examination or laboratory screening&#xD;
             tests&#xD;
&#xD;
          8. Acute or chronic diabetes&#xD;
&#xD;
          9. History of chronic alcohol consumption and/or intravenous drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blaise Genton, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss tropical institute, Ifakara Health Research and Development Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bagamoyo Research and Training Unit</name>
      <address>
        <city>Bagamoyo</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <link>
    <url>http://www.sti.ch</url>
    <description>Website of the Swiss Tropical Institute</description>
  </link>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Falciparum</keyword>
  <keyword>Trial</keyword>
  <keyword>Phase I</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

